Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BMS-986393 |
| Trade Name | |
| Synonyms | CC-95266|CC 95266|CC95266|BMS 986393|BMS986393 |
| Drug Descriptions |
BMS-986393 (CC-95266) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting GPRC5D, which potentially results in antitumor activity (Blood (2022) 140 (Supplement 1): 883-885). |
| DrugClasses | GPRC5D Immune Cell Therapy 4 |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BMS-986393 | BMS-986393 | 0 | 1 |
| BMS-986393 + Carfilzomib + Daratumumab + Dexamethasone + Pomalidomide | BMS-986393 Carfilzomib Daratumumab Dexamethasone Pomalidomide | 0 | 1 |
| BMS-986393 + CC-92480 | BMS-986393 CC-92480 | 0 | 1 |
| BMS-986393 + CC-93269 | BMS-986393 CC-93269 | 0 | 1 |
| BMS-986393 + Cyclophosphamide + Fludarabine | BMS-986393 Cyclophosphamide Fludarabine | 0 | 1 |
| BMS-986393 + Elranatamab-bcmm | BMS-986393 Elranatamab-bcmm | 0 | 1 |
| BMS-986393 + Iberdomide | BMS-986393 Iberdomide | 0 | 1 |